DA Cooper

1.2k total citations
23 papers, 792 citations indexed

About

DA Cooper is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, DA Cooper has authored 23 papers receiving a total of 792 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Infectious Diseases, 12 papers in Virology and 7 papers in Epidemiology. Recurrent topics in DA Cooper's work include HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (10 papers) and HIV/AIDS Research and Interventions (5 papers). DA Cooper is often cited by papers focused on HIV Research and Treatment (12 papers), HIV/AIDS drug development and treatment (10 papers) and HIV/AIDS Research and Interventions (5 papers). DA Cooper collaborates with scholars based in Australia, United Kingdom and Netherlands. DA Cooper's co-authors include Andrew Carr, Janaki Amin, Sean Emery, Patrick Mallon, William A. Sewell, Ronald Penny, Jennifer Turner, Matthew Law, Deenan Pillay and Matthew Kaye and has published in prestigious journals such as Blood, Clinical Pharmacology & Therapeutics and Journal of the International AIDS Society.

In The Last Decade

DA Cooper

22 papers receiving 766 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
DA Cooper Australia 13 435 290 259 227 216 23 792
Gerd Fätkenheuer Germany 14 576 1.3× 194 0.7× 528 2.0× 209 0.9× 155 0.7× 38 908
Álvaro H. Borges Denmark 13 424 1.0× 481 1.7× 336 1.3× 233 1.0× 210 1.0× 37 936
Jesús Santos Spain 14 270 0.6× 71 0.2× 85 0.3× 267 1.2× 135 0.6× 44 668
Jorge Benetucci Argentina 15 417 1.0× 183 0.6× 354 1.4× 184 0.8× 60 0.3× 35 646
Barbara Bertisch Switzerland 12 434 1.0× 398 1.4× 165 0.6× 461 2.0× 141 0.7× 29 856
Laurence Héripret France 8 274 0.6× 94 0.3× 127 0.5× 319 1.4× 139 0.6× 11 597
E. Mortier France 13 236 0.5× 41 0.1× 139 0.5× 180 0.8× 100 0.5× 37 534
Stephen Kravcik Canada 11 666 1.5× 216 0.7× 668 2.6× 206 0.9× 53 0.2× 17 941
P. de Truchis France 10 351 0.8× 147 0.5× 251 1.0× 201 0.9× 31 0.1× 20 589
Carmela Pinnetti Italy 17 596 1.4× 173 0.6× 300 1.2× 340 1.5× 44 0.2× 91 921

Countries citing papers authored by DA Cooper

Since Specialization
Citations

This map shows the geographic impact of DA Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by DA Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites DA Cooper more than expected).

Fields of papers citing papers by DA Cooper

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by DA Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by DA Cooper. The network helps show where DA Cooper may publish in the future.

Co-authorship network of co-authors of DA Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of DA Cooper. A scholar is included among the top collaborators of DA Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with DA Cooper. DA Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Cooper, DA, Peter Reiss, Keith Henry, et al.. (2010). The effects of enfuvirtide therapy on body composition and metabolic parameters over 48 weeks in the TORO body imaging substudy*. HIV Medicine. 12(1). 31–39. 12 indexed citations
3.
Cahn, Pedro, Javier Altclas, Marcelo Martins, et al.. (2010). Antiviral activity of apricitabine in treatment-experienced HIV-1-infected patients with M184V who are failing combination therapy. HIV Medicine. 12(6). 334–342. 2 indexed citations
4.
Carey, Dianne, David Baker, Kathy Petoumenos, et al.. (2009). Poly‐l‐lactic acid for HIV‐1 facial lipoatrophy: 48‐week follow‐up. HIV Medicine. 10(3). 163–172. 12 indexed citations
5.
Cahn, Pedro, Javier Altclas, Maria Isabel Morgan Martins, et al.. (2008). O414 48-week data from Study AVX-201 – a randomised phase IIb study of apricitabine in treatment-experienced patients with M184V and NRTI resistance. Journal of the International AIDS Society. 11(S1). 4 indexed citations
6.
Avihingsanon, Anchalee, Jasper van der Lugt, Stephen J. Kerr, et al.. (2008). A Low Dose of Ritonavir-Boosted Atazanavir Provides Adequate Pharmacokinetic Parameters in HIV-1-Infected Thai Adults. Clinical Pharmacology & Therapeutics. 85(4). 402–408. 29 indexed citations
7.
Calmy, Alexandra, Dianne Carey, Patrick Mallon, et al.. (2008). Early changes in adipokine levels and baseline limb fat may predict HIV lipoatrophy over 2 years following initiation of antiretroviral therapy*. HIV Medicine. 9(2). 101–110. 8 indexed citations
8.
Byakwaga, Helen, John M. Murray, Kathy Petoumenos, et al.. (2008). Evolution of CD4+ T-cell count in HIV-1 infected adults receiving antiretroviral therapy with sustained long-term virological suppression. Journal of the International AIDS Society. 11(S1). 2 indexed citations
9.
Cooper, DA, et al.. (2007). The public health impact of widespread availability of nonoccupational postexposure prophylaxis against HIV. HIV Medicine. 8(6). 374–381. 28 indexed citations
10.
Winston, Alan, Janaki Amin, Patrick Mallon, et al.. (2006). Minor changes in calculated creatinine clearance and anion‐gap are associated with tenofovir disoproxil fumarate‐containing highly active antiretroviral therapy. HIV Medicine. 7(2). 105–111. 78 indexed citations
11.
Winston, Alan, John McAllister, Janaki Amin, DA Cooper, & Andrew Carr. (2005). The use of a triple nucleoside‐nucleotide regimen for nonoccupational HIV post‐exposure prophylaxis. HIV Medicine. 6(3). 191–197. 38 indexed citations
12.
Amin, Janaki, et al.. (2004). HIV and hepatitis C coinfection within the CAESAR study. HIV Medicine. 5(3). 174–179. 113 indexed citations
13.
Miller, J. Philip, Andrew Carr, Sean Emery, et al.. (2003). HIV lipodystrophy: prevalence, severity and correlates of risk in Australia. HIV Medicine. 4(3). 293–301. 159 indexed citations
14.
Biti, Robyn A., et al.. (2002). Heterozygosity for CCR5‐DΔ32 but not CCR2b‐64I protects against certain intracellular pathogens. HIV Medicine. 3(2). 91–96. 15 indexed citations
15.
Mallon, Patrick, DA Cooper, & Andrew Carr. (2001). HIV‐associated lipodystrophy. HIV Medicine. 2(3). 166–173. 43 indexed citations
16.
Colebunders, Robert, Ian Weller, Jonathan Weber, et al.. (2001). Therapeutic vaccination (p24‐VLP) of patients with advanced HIV‐1 infection in the pre‐HAART era does not alter CD4 cell decline. HIV Medicine. 2(4). 272–275. 20 indexed citations
17.
Boyle, Michelle J., E Vasak, Jennifer Turner, et al.. (1993). Subtypes of Epstein-Barr virus (EBV) in Hodgkin's disease: association between B-type EBV and immunocompromise [see comments]. Blood. 81(2). 468–474. 47 indexed citations
18.
Sewell, William A., et al.. (1991). Subtypes of Epstein-Barr virus in human immunodeficiency virus- associated non-Hodgkin lymphoma. Blood. 78(11). 3004–3011. 113 indexed citations
19.
Cooper, DA. (1983). Epidemic Kaposi's sarcoma and opportunistic infections.. PubMed. 1(12). 564–6. 6 indexed citations
20.
Cooper, DA. (1979). The immunological basis of immediate hypersensitivity.. PubMed. 8(1). 38–9, 41.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Gerd Fätkenheuer Breakdown of academic impact, for papers by Álvaro H. Borges Breakdown of academic impact, for papers by Jesús Santos Breakdown of academic impact, for papers by Jorge Benetucci Breakdown of academic impact, for papers by Barbara Bertisch Breakdown of academic impact, for papers by Laurence Héripret Breakdown of academic impact, for papers by E. Mortier Breakdown of academic impact, for papers by Stephen Kravcik Breakdown of academic impact, for papers by P. de Truchis Breakdown of academic impact, for papers by Carmela Pinnetti
Rankless by CCL
2026